Therefore, both increased TIL levels and increased expression of PD-L1 in the tumor tissues can serve as surrogate biomarkers of immunogenicity of cancer cells and interactions between cancer cells and immune cells or of the presence of adaptive immune resistance [58, 60, 61]. The gene discussed is CD274; the disease is neoplasm.